HUMAN MONOCLONAL ANTIBODIES TO TNF-? — AGENT OF CHOICE IN TREATMENT OF SEVERE JUVENILE RHEUMATOID ARTHRITIS WITH UVEITIS
Abstract
The article presents a case report of an early debut and severe clinical course of juvenile rheumatoid arthritis with eyes’ lesion. Authors describe successful administration of human monoclonal antibodies to tumor necrotizing factor (TNF) — adalimumab. In 2 weeks of treatment the morning joint stiffness was stopped, in 4 weeks exudative alterations in affected joints were vanished, and the range of their motions increased. Results of laboratory tests: ESR and concentration of C-reactive protein in plasma were normalized in 6 weeks. Adalimumab initiated development of remission of bilateral uveitis in 8 weeks.
Key words: children, juvenile rheumatoid arthritis, rheumatoid uveitis, adalimumab, treatment.
(Voprosy sovremennoi pediatrii — Current Pediatrics. – 2010;9(3):140-146)
About the Authors
A.O. LisitsynRussian Federation
E.I. Alexeeva
Russian Federation
S.I. Valieva
Russian Federation
T.M. Bzarova
Russian Federation
R.V. Denisova
Russian Federation
N.А. Karagulyan
Russian Federation
A.M. Chomachidze
Russian Federation
K.B. Isaeva
Russian Federation
References
1. Cassidy J.T, Petty R.E., Laxer R.M. et al. Textbook of Pediatric Rheumatology 5th ed. Philadelphia: W.B. Saunders. 2005.
2. BenEzra D., Cohen E., Maftzir G. Uveitis in children and adolescents. British. J. Ophthalmology. 2006; 89: 444–448.
3. Foster C.S. Diagnosis and treatment of juvenile idiopathic arthritis
4. associated uveitis. Current Opin. Ophthalmol. 2003; 14: 395–398.
5. Катаргина Л.А., Архипова Л.Т. Увеиты: патогенетическая иммуносупрессивная терапия. М.: Триада. 2004. 100 с.
6. Педиатрия. Под ред. А.А. Баранова. М.: ГЭОТАР–Медиа. 2009. 432 с.
7. Lahdenne P., Vahasalo P., Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann. Rheum. Dis. 2003; 62: 245–247.
8. Corona F., Scarazatti M., Dell’erra L. et al. Active refractory juvenile idiopathic arthritis: treatment with infliximab. Efficacy and safety. Ital. J. Pediatr. 2004; 30: 165–168.
9. Lahdenne P., Vahasalo P., Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann. Rheum. Dis. 2003; 62: 245–247.
10. Алексеева Е.И., Слепцова Т.В., Валиева С.И. и др. Эффективность и безопасность инфликсимаба у больных ранним ювенильным ревматоидным артритом. Вопросы современной педиатрии. 2009; 8 (4): 42–50.
11. Alexeeva E.I., Lomakina O., Denisova R. et al. Safety and efficacy of adalimumab therapy for refractory juvenile idiopathic arthritis — associated chronic uveitis. Aabstract in the 4rd Europaediatrics Congress, 3–6 July. Moscow. 2009. P. 365.
12. Daniel J.L., Nicola R., Steven G. et al. Preliminary Data from the Study of Adalimumab in Children with Juvenile Idiopathic Arthritis (JIA). Abstract presented at Pediatric American College of Rheumatology. 2004. Presentation Number: 1096.
13. Lovell D.J., Ruperto N., Goodman S. et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N. Engl. J. Med. 2008; 359 (8): 810–820.
14. Tynjälä P., Kotaniemi K., Lindahl P. et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology. 2008; 47: 339–344.
15. Vazquez–Cobian L.B., Flynn T., Lehman T.J.A. Adalimumab therapy for childhood uveitis. J Pediatr. 2006; 149: 572–575.
16. Biester S., Deuter C., Michels H. et al. Adalimumab in the therapy of uveitis in childhood. Br. J. Ophthalmol. 2007; 91 (3): 319–324.
17. Diaz-Llopis M., García-Delpech S., Salom D. et al. Adalimumab therapy for refractory uveitis: a pilot study. J. Ocul. Pharmacol. Ther. 2008; 24 (3): 351-61.
18. Лисицин А.О., Алексеева Е.И., Бзарова Т.М. и др. Опыт применения адалимумаба у больной юношеским полиартритом с поражением глаз. Вопросы современной педиатрии. 2008; 7 (5): 115–120.
19. Алексеева Е.И., Валиева С.И., Бзарова Т.М. и др. Опыт применения адалимумаба у больного юношеским анкилозирующим спондилитом с поражением глаз. Вопросы современной педиатрии. 2009; 8 (1): 135–141.
20. Лисицин А.О., Алексеева Е.И., Валиева С.И. и др. Опыт применения человеческих моноклональных антител к ФНО α у больной ювенильным ревматоидным артритом с увеитом. Вопросы современной педиатрии. 2009; 8 (6): 151–157.
21. Алексеева Е.И., Лисицин А.О., Карагулян Н.А. и др. Адалимумаб: новые возможности лечения ювенильного артрита. Вопросы современной педиатрии. 2009; 8 (3): 88–94.
Review
For citations:
Lisitsyn A., Alexeeva E., Valieva S., Bzarova T., Denisova R., Karagulyan N., Chomachidze A., Isaeva K. HUMAN MONOCLONAL ANTIBODIES TO TNF-? — AGENT OF CHOICE IN TREATMENT OF SEVERE JUVENILE RHEUMATOID ARTHRITIS WITH UVEITIS. Current Pediatrics. 2010;9(3):140-146.
Email this article 
